Moderna (NASDAQ: MRNA) reported Q2 EPS of $6.46, $0.42 better than the analyst estimate of $6.04. Revenue for the quarter came in at $4.35 billion versus the consensus estimate of $4.28 billion.

• Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose ​

For earnings history and earnings-related data on Moderna (MRNA) click here.